SuspendedPhase 2

Neuroinflammation in Patients With OCD

Stopped: The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research on March 14, 2024.

United States21 participantsStarted 2021-04-01

Plain-language summary

The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding to ongoing medication-based treatment for OCD.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 to 55 years old * Principal diagnosis of Obsessive-Compulsive Disorder (OCD) * Ongoing OCD symptoms despite current treatment with psychiatric medication * Capacity to provide informed consent Exclusion Criteria: * Psychiatric comorbidities that would increase risk of participation or impact research measures (e.g., suicidality) * Medical or neurological conditions that would increase risk of participation or impact research measures * Contraindications to an MRI or PET scan (e.g., metal implants) * Current use of medications that may interact with study drug or impact research measures (e.g., antipsychotics, corticosteroids, immunosuppressant medications, or daily non-steroidal anti-inflammatory medications) * Starting a new evidence-based therapy for OCD (e.g., exposure with response prevention) 4 weeks prior to study enrollment

What they're measuring

Yale-Brown Obsessive Compulsive Scale

Timeframe: Week 8

Trial details

NCT IDNCT04786548

SponsorNew York State Psychiatric Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08

View on ClinicalTrials.gov More Obsessive-Compulsive Disorder trials